MarketPulse

VYKAT™ XR

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno's VYKAT XR Faces Legal Storm as Safety Concerns Tank Stock 40%

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.
SLNOstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno Therapeutics Hit With Class Action Over VYKAT Launch Failures and Safety Disclosures

$SLNO faces securities lawsuit alleging misleading safety claims for hyperphagia drug VYKAT XR. Stock crashed 40% after short seller report and management admissions of launch disruptions.
SLNOsecurities class actionclinical trial